AstraZeneca Historical Income Statement
AZN Stock | USD 75.17 0.14 0.19% |
Historical analysis of AstraZeneca PLC income statement accounts such as Interest Expense of 1.7 B, Total Revenue of 24.2 B or Gross Profit of 19.9 B can show how well AstraZeneca PLC ADR performed in making a profits. Evaluating AstraZeneca PLC income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of AstraZeneca PLC's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining AstraZeneca PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AstraZeneca PLC ADR is a good buy for the upcoming year.
AstraZeneca |
About AstraZeneca Income Statement Analysis
AstraZeneca PLC ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to AstraZeneca PLC shareholders. The income statement also shows AstraZeneca investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
AstraZeneca PLC Income Statement Chart
AstraZeneca PLC ADR Income Statement is one of the three primary financial statements used for reporting AstraZeneca's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of AstraZeneca PLC ADR revenue and expense. AstraZeneca PLC Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, AstraZeneca PLC's Interest Income is very stable compared to the past year. Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts AstraZeneca PLC ADR generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of AstraZeneca PLC ADR minus its cost of goods sold. It is profit before AstraZeneca PLC operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of AstraZeneca PLC ADR. It is also known as AstraZeneca PLC overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from AstraZeneca PLC ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of AstraZeneca PLC ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from AstraZeneca PLC's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. At this time, AstraZeneca PLC's Interest Income is very stable compared to the past year.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.3B | 1.3B | 1.6B | 1.7B | Depreciation And Amortization | 6.5B | 5.6B | 4.9B | 5.2B |
AstraZeneca PLC income statement Correlations
Click cells to compare fundamentals
AstraZeneca PLC Account Relationship Matchups
High Positive Relationship
High Negative Relationship
AstraZeneca PLC income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 4.1B | 3.2B | 6.5B | 5.6B | 4.9B | 5.2B | |
Interest Expense | 1.4B | 1.3B | 1.3B | 1.3B | 1.6B | 1.7B | |
Total Revenue | 24.4B | 26.6B | 37.4B | 44.4B | 45.8B | 24.2B | |
Gross Profit | 19.5B | 21.3B | 25.0B | 32.0B | 37.5B | 19.9B | |
Other Operating Expenses | 21.2B | 21.5B | 36.4B | 40.6B | 37.1B | 19.0B | |
Operating Income | 2.9B | 5.2B | 1.1B | 3.8B | 8.2B | 5.0B | |
Ebit | 2.9B | 5.2B | 1.1B | 3.8B | 9.0B | 5.4B | |
Research Development | 6.0B | 6.0B | 9.7B | 9.8B | 10.9B | 11.5B | |
Ebitda | 7.0B | 8.4B | 7.6B | 9.3B | 13.9B | 7.7B | |
Total Operating Expenses | 16.3B | 16.2B | 23.9B | 28.2B | 28.8B | 14.7B | |
Income Before Tax | 1.5B | 3.9B | (265M) | 2.5B | 6.9B | 4.5B | |
Total Other Income Expense Net | (1.4B) | (1.2B) | (1.3B) | (1.3B) | (1.3B) | (1.2B) | |
Net Income | 1.3B | 3.2B | 112M | 3.3B | 6.0B | 3.5B | |
Income Tax Expense | 321M | 772M | (380M) | (792M) | 938M | 729.2M | |
Selling General Administrative | 9.0B | 11.7B | 15.7B | 19.0B | 18.2B | 11.8B | |
Cost Of Revenue | 4.9B | 5.3B | 12.4B | 12.4B | 8.3B | 6.4B | |
Net Income Applicable To Common Shares | 1.3B | 3.2B | 112M | 3.3B | 3.0B | 3.2B | |
Minority Interest | 1.5B | 16M | (3M) | (5M) | (6M) | (5.7M) | |
Selling And Marketing Expenses | 11.8B | 11.7B | 15.7B | 19.0B | 18.2B | 11.9B | |
Net Income From Continuing Ops | 1.2B | 3.1B | 115M | 3.3B | 6.0B | 6.3B | |
Tax Provision | 321M | 772M | (380M) | (792M) | 938M | 984.9M | |
Interest Income | 774M | 87M | 43M | 95M | 301M | 342.8M | |
Net Interest Income | (1.2B) | (1.2B) | (1.3B) | (1.3B) | (1.3B) | (1.4B) | |
Reconciled Depreciation | 3.8B | 3.1B | 6.5B | 5.5B | 4.9B | 4.8B |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
0.63 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
Moving against AstraZeneca Stock
0.68 | INTC | Intel Financial Report 25th of July 2024 | PairCorr |
0.56 | MCD | McDonalds Financial Report 25th of July 2024 | PairCorr |
0.49 | PFE | Pfizer Inc Earnings Call This Week | PairCorr |
0.41 | HD | Home Depot Financial Report 21st of May 2024 | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the AstraZeneca PLC ADR information on this page should be used as a complementary analysis to other AstraZeneca PLC's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Complementary Tools for AstraZeneca Stock analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is AstraZeneca PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.207 | Dividend Share 2.9 | Earnings Share 2.02 | Revenue Per Share 2.5512 | Quarterly Revenue Growth 0.165 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.